This suggests that the advantage of using MSC-based in situ production of soluble TRAIL is not only favorable to overcome the short plasma half-lives of this antitumor drug but also may contribute to break TRAIL resistance of tumor cells. The gene discussed is TNFSF10; the disease is neoplasm.